Case Study
Abstract: A biotech company engaged WuXi TIDES to develop a siRNA-GalNAc drug candidate for cardiovascular disease. The original synthesis process for this 23-mer siRNA resulted in a yield…
Abstract: A biotech company engaged WuXi TIDES to develop a siRNA-GalNAc drug candidate for cardiovascular disease. The original synthesis process for this 23-mer siRNA resulted in a yield of 13% and a crude purity of 18%. In addition, the GalNAc moiety was not commercially available. Our team’s objective was to accelerate this challenging molecule to IND filing as fast as possible. Utilizing innovative conjugation chemistry and tailored analytical studies, we significantly improved the crude purity and yield to 75% and 62%, respectively, delivering on this project in a timely and efficient manner.
Keep reading
Process mass intensity (PMI) is one of the most important metrics in sustainable manufacturing. It measures the total mass of raw materials required to produce a given mass of product. In…
As GLP-1 receptor agonists continue to redefine treatment for metabolic diseases, drug developers are racing to bring new and more complex therapies to the clinic. But innovation alone is…
A new publication by MSD in Organic Process Research & Development details the process development and large-scale manufacturing of the key Northern Fragment of Enlicitide Decanoate.
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA